Trial reportScience translational medicine2009
Efficacy of cetuximab in the treatment of Menetrier's disease.
Trial report in Science translational medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 78 citations in OpenAlex.
- [18F]FLT-PET to predict pharmacodynamic and clinical response to cetuximab therapy in Ménétrier's disease.Annals of nuclear medicine · 2012Trial
- Rare Coexistence of Ménétrier's Disease and Gallbladder Duplication in a Young Male Adult: A Case Report.Diagnostics (Basel, Switzerland) · 2026Article
- Ménétrier's disease with coexistent signet ring cell carcinoma: a rare presentation with peritoneal metastasis.BMJ case reports · 2026Article
- Transcriptomic profiling reveals the role of Hedgehog signaling as a biomarker and in the pathogenesis of Ménétrier's disease.The Journal of pathology · 2026Article
- Ménétrier disease: A clinical review.World journal of gastroenterology · 2025Review
- From Chronic Anemia to Total Gastrectomy: A Case Report on a Challenging Form of Ménétrier's Disease.Cureus · 2025Article
- Development of Mouse Models for Ménétrier's Disease.Journal of visualized experiments : JoVE · 2025Article
- Article
- Clinical and Radiological Features of Menetrier's Disease: A Case Report and Review of the Literature.Cureus · 2023Article
- Upper gastrointestinal bleeding as an unusual manifestation of localized Ménétrier's disease with an underlying lipoma: A case report.World journal of gastrointestinal endoscopy · 2023Article
- Menetrier's disease exacerbating ulcerative colitis and relieved by gastrectomy.BMJ open gastroenterology · 2021Article
- Article
- Ménétrier-like disease in a Pointer with concurrent granulomatous gastritis, helicobacteriosis and leishmaniosis: a case report.BMC veterinary research · 2021Article
- Article
- Identification and Characterization of Unique Neutralizing Antibodies to Mouse EGF Receptor.Gastroenterology · 2020Article
- Total gastrectomy for the treatment of Menetrier's disease persistent to medical therapy: A case report.International journal of surgery case reports · 2020Article
- A Misdiagnosed Case of Hypertrophic Gastropathy.Case reports in pathology · 2020Article
- A case of Ménétriere´s disease treated with the monoclonal antibody cetuximab.Clinical journal of gastroenterology · 2019Article
- Ménétrier's disease presenting as recurrent unprovoked venous thrombosis: a case report.Journal of medical case reports · 2019Article
- A Rare Etiology of Abnormally Large Gastric Folds: Menetrier's Disease.Case reports in gastrointestinal medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
Ménétrier's disease is a rare premalignant disorder of the stomach with no proven effective medical therapy. Increased epidermal growth factor receptor signaling has been implicated in the pathogenesis of Ménétrier's disease. We conducted a single-arm clinical trial with cetuximab, a monoclonal antibody that blocks epidermal growth factor receptor signaling, in nine individuals with clinically and histologically documented severe Ménétrier's disease that impaired quality of life to the extent that gastrectomy was being considered. Of the seven patients who completed the 1-month course of treatment, all showed statistically significant improvement both clinically (quality-of-life indices) and biochemically (increased parietal cell mass and gastric acidity). Furthermore, all seven patients who completed the 1-month trial elected to continue treatment, and four subsequently showed near-complete histological remission. Cetuximab should be considered as first-line therapy for Ménétrier's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.